{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"3"}],"units":"Participants"}],"description":"DLT was defined as adverse events occurring during Cycle 1 and: (1) Grade 3 or higher nausea, vomiting, or diarrhea despite the use of anti-emetic or antidiarrheal drugs, (2) Grade 3 or higher non-hematologic toxicity, excluding alopecia, (3) AEs requiring interruption of the IMP for a total of 8 days or longer, (4) Grade 4 neutropenia lasting ≥ 8 days (not applicable for leukemia), (5) Grade 3 or higher febrile neutropenia or infection due to neutropenia (not applicable for leukemia), (6) Grade 4 thrombocytopenia or Grade 3 thrombocytopenia requiring platelet transfusion (not applicable for leukemia).","groups":[{"description":"OPB-51602: 1, 2, 3, 4 and 6 mg/day oral once daily (QD) in a 4 week cycle","id":"OG000","title":"OPB-51602 1m/Day"},{"description":"OPB-51602: 1, 2, 3, 4 and 6 mg/day oral once daily (QD) in a 4 week cycle","id":"OG001","title":"OPB-51602 2mg/Day"},{"description":"OPB-51602: 1, 2, 3, 4 and 6 mg/day oral once daily (QD) in a 4 week cycle","id":"OG002","title":"OPB-51602 3mg/Day"},{"description":"OPB-51602: 1, 2, 3, 4 and 6 mg/day oral once daily (QD) in a 4 week cycle","id":"OG003","title":"OPB-51602 4mg/Day"},{"description":"OPB-51602: 1, 2, 3, 4 and 6 mg/day oral once daily (QD) in a 4 week cycle","id":"OG004","title":"OPB-51602 6mg/Day"}],"paramType":"NUMBER","populationDescription":"DLT evaluated subjects who had achieved ≧75% study drug compliance during a 4-week (28-day) treatment period starting from Day 4. No statistical analysis provided for Subjects With DLTs.","reportingStatus":"POSTED","timeFrame":"From first study medication to on Day 31 (after repeated 28 days medication from Day 4 to 31)","title":"Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs)","type":"PRIMARY","unitOfMeasure":"participants"}